📣 VC round data is live. Check it out!

Stratec Valuation Multiples

Discover Stratec's revenue and EBITDA valuation multiples and M&A history, alongside public comparables like Dong-A ST, Profound Medical, Affluent Medical, Sight Sciences and more.

Stratec Overview

About Stratec

Stratec SE designs and manufactures automated analyzer systems for laboratory data management and solutions for molecular diagnostic sample preparation and stabilization. Its business segments are Instrumentation, Diatron and Smart Consumables. Its Instrumentation segment is engaged in designing and manufacturing automated analyzer systems for clinical diagnostics and biotechnology customers. The Diatron segment comprises the business with systems, system components, consumables, and tests in the low throughput hematology and clinical chemistry segment. Its Smart Consumables segment is engaged in developing and selling scientific materials, such as nucleic acid purification. The company generates maximum revenue from the Instrumentation segment.


Founded

1979

HQ

Germany

Employees

1.4K

Financials (LTM)

Revenue: $299M
EBITDA: $42M

EV

$367M

Valuation Multiples

Start free trial

Valuation Multiples for 15K+ Public Comps

AdidasAirbnbAmazonCiscoCoca-ColaDellDropboxIBMIntelMcDonaldsNikeNVIDIASamsungSpotifyTeslaToyota
Browse Valuation Multiples

Stratec Financials

Stratec reported last 12-month revenue of $299M and EBITDA of $42M.

In the same LTM period, Stratec generated $79M in gross profit, $42M in EBITDA, and $7M in net income.

Revenue (LTM)


Stratec P&L

In the most recent fiscal year, Stratec reported revenue of $294M and EBITDA of $40M.

Stratec is unprofitable as of last fiscal year, with gross margin of 25%, EBITDA margin of 14%, and net margin of (0%).

See analyst estimates for Stratec
LTMLast FY202320242025202620272028
Revenue$299M$294M$305M$300M$292M
Gross Profit$79M$75M$75M$89M$75M
Gross Margin26%25%25%30%26%
EBITDA$42M$40M$46M$55M$39M
EBITDA Margin14%14%15%18%13%
EBIT Margin6%4%10%11%4%
Net Profit$7M($188K)$15M$19M($282K)
Net Margin2%(0%)5%6%(0%)
Net Debt-$112M---

Financial data powered by Morningstar, Inc.

Stratec Stock Performance

Stratec has current market cap of $242M, and enterprise value of $367M.

Market Cap Evolution


Stratec's stock price is $19.90.

Stratec share price decreased by 3.5% in the last 30 days, and by 34.2% in the last year.

Stratec has an EPS (earnings per share) of $-0.02.

See more trading valuation data for Stratec
EVMarket CapPrice 1DPrice 1MPrice 3MPrice 12MEPS
$367M$242M-3.4%-3.5%-1.5%-34.2%$-0.02

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.

Start Free Trial

Stratec Valuation Multiples

Stratec trades at 1.2x EV/Revenue multiple, and 8.7x EV/EBITDA.

See NTM and 2027E valuation multiples for Stratec

EV / Revenue (LTM)


Stratec Financial Valuation Multiples

As of June 3, 2026, Stratec has market cap of $242M and EV of $367M.

Stratec has a P/E ratio of 37.1x.

LTMLast FY202320242025202620272028
EV/Revenue1.2x1.3x1.2x1.2x1.3x
EV/EBITDA8.7x9.1x7.9x6.7x9.3x
EV/EBIT21.6x29.5x12.4x11.2x29.5x
EV/Gross Profit4.7x4.9x4.9x4.1x4.9x
P/E37.1xn/m15.9x13.0xn/m
EV/FCFn/m(24.8x)157.7x10.3x(18.9x)

Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Verified Stratec Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.

FactSetMorningstar
Start Free Trial

Stratec Margins & Growth Rates

Stratec grew revenue by 5% and EBITDA by 11% in the last fiscal year.

In the most recent fiscal year, Stratec reported gross margin of 25%, EBITDA margin of 14%, and net margin of (0%).

See estimated margins and future growth rates for Stratec

Stratec Margins

Last FY202420252026202720282029
Gross Margin25%30%26%27%
EBITDA Margin14%18%13%15%
EBIT Margin4%11%4%8%
Net Margin(0%)6%(0%)5%
FCF Margin(5%)12%(7%)6%

Stratec Growth Rates

FY+1/FY23/2424/2525/2626/2727/2828/29
Revenue Growth5%(2%)(3%)5%
Gross Profit Growth13%18%(16%)13%
EBITDA Growth11%19%(29%)14%
EBIT Growth107%11%(62%)107%
Net Profit Growth(8449%)23%(102%)(5681%)
FCF Growth(227%)1425%(155%)(197%)

Data powered by FactSet, Inc. and Morningstar, Inc.

Stratec Operational KPIs

Stratec's revenue per employee in the last FY averaged $0.2M, while opex per employee averaged $0.0M for the same period.

Stratec's Rule of 40 is 20% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Stratec's Rule of X is 28% (created by Bessemer, Rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

Access forward-looking KPIs for Stratec
LTMLast FY202320242025202620272028
Rule of 4020%20%---
Bessemer Rule of X28%28%---
Revenue per Employee-$0.2M---
Opex per Employee-$0.0M---
S&M Expenses to Revenue5%5%5%5%5%
G&A Expenses to Revenue10%10%7%9%10%
R&D Expenses to Revenue6%6%3%5%6%
Opex to Revenue-21%15%19%21%

Data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 230+ Verticals

Stratec Competitors

Stratec competitors include Dong-A ST, Profound Medical, Affluent Medical, Sight Sciences, Median Technologies, Orchestra BioMed, Carvolix, Eurobio Scientific, Treace Medical Concepts and Onward Medical.

Most Stratec public comparables operate across Medical Devices, DeepTech and HealthTech.

EV/RevenueEV/EBITDA
Last FYLTM2027ELast FYLTM2027E
Dong-A ST0.8x0.8x11.0x10.4x
Profound Medical12.1x9.6x(5.3x)(5.8x)
Affluent Medical-372.7x-(11.9x)
Sight Sciences2.5x2.4x(7.4x)(7.8x)
Median Technologies9.3x8.8x(13.7x)(13.8x)
Orchestra BioMed4.6x7.9x(3.0x)(2.2x)
Carvolix57.0x401.8x(19.6x)(12.8x)
Eurobio Scientific1.3x1.3x7.8x7.3x

This data is available for Pro users. Sign up to see all Stratec competitors and their valuation data.

Start Free Trial

Acquisitions by Stratec

Stratec has acquired 2 companies to date.

Last acquisition by Stratec was on June 7th 2023. Stratec acquired Natech Plastics for $30M (EV/Revenue multiple available to Pro users).

See M&A valuation multiples

Latest Acquisitions by Stratec

Natech Plastics
Diatron
Description
Natech Plastics is a Plymouth, Minnesota-based manufacturer specializing in injection-molded plastic components for medical devices and diagnostics. The company operates three facilities equipped with ISO Class 8 cleanrooms for assembly and production. Natech holds ISO 9001 and 13485 certifications plus FDA registration, enabling full device manufacturing for startups. Services include design for manufacturability, prototyping, and high-volume runs for OEMs in orthopedics and in-vitro diagnostics.
Diatron is a Budapest-headquartered group that produces compact hematology analyzers for human and veterinary diagnostics. Its Aquios and Mediplus series analyzers perform CBC, 5-part differentials, and reticulocyte counts, serving laboratories in over 60 countries across five continents. Diatron maintains production in Hungary and sales operations in Austria.
HQ CountryUnited StatesHungary
HQ City
New York City, NY
Budapest
Deal Date7 Jun 202323 Mar 2016
Valuation$30Mundisclosed
EV/Revenue
EV/EBITDA

This data is available for Pro users. Sign up to see all Stratec acquisitions and their M&A valuation multiples.

Start Free Trial

Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples

Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.

Start Free Trial

About Stratec

When was Stratec founded?Stratec was founded in 1979.
Where is Stratec headquartered?Stratec is headquartered in Germany.
How many employees does Stratec have?As of today, Stratec has over 1K employees.
Is Stratec publicly listed?Yes, Stratec is a public company listed on Frankfurt Stock Exchange.
What is the stock symbol of Stratec?Stratec trades under SBS ticker.
When did Stratec go public?Stratec went public in 1998.
Who are competitors of Stratec?Stratec main competitors include Dong-A ST, Profound Medical, Affluent Medical, Sight Sciences, Median Technologies, Orchestra BioMed, Carvolix, Eurobio Scientific, Treace Medical Concepts, Onward Medical.
What is the current market cap of Stratec?Stratec's current market cap is $242M.
What is the current revenue of Stratec?Stratec's last 12 months revenue is $299M.
What is the current revenue growth of Stratec?Stratec revenue growth (NTM/LTM) is 5%.
What is the current EV/Revenue multiple of Stratec?Current revenue multiple of Stratec is 1.2x.
What is the current EBITDA of Stratec?Stratec's last 12 months EBITDA is $42M.
What is Stratec's EBITDA margin?Stratec's last 12 months EBITDA margin is 14%.
What is the current EV/EBITDA multiple of Stratec?Current EBITDA multiple of Stratec is 8.7x.
What is the current FCF of Stratec?Stratec's last 12 months FCF is ($602K).
What is Stratec's FCF margin?Stratec's last 12 months FCF margin is (0%).
What is the current EV/FCF multiple of Stratec?Current FCF multiple of Stratec is (609.9x).
How many companies Stratec has acquired to date?As of June 2026, Stratec has acquired 2 companies.
What was the largest acquisition by Stratec?$30M acquisition of Natech Plastics on 7th June 2023 was the largest M&A Stratec has done to date.
What companies Stratec acquired?Stratec acquired Natech Plastics and Diatron.
In how many companies Stratec has invested to date?Stratec hasn't invested in any companies yet (or none have been disclosed publicly).

See public comps similar to Stratec

Lists including Stratec

Start Your
Free Trial Today

Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

Start Trial